Close Cookie Popup
Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Biotech

Biotech

From small molecules to novel gene therapies and from oncology to rare diseases, learn more about our biotech innovations.

Biotech
From invention to innovation / Biotech
00:00
/
00:00
00:00
/
00:00
From invention to innovation

We find opportunities in academic institutions through our extensive network of universities and tech transfer offices. Thousands of projects are sourced, assessed, and selected each year, evaluating their scientific and commercial potential. Our team brings decades of combined expertise from academia, drug development, and commercial and business environments across all major therapeutic areas.

Expert-driven venture development / biotech
00:00
/
00:00
00:00
/
00:00
Expert-driven venture building

We build successful therapeutics and diagnostics ventures around groundbreaking science. By providing our expertise, initial capital, and NLC’s supporting ecosystem, we create value for early-stage projects. Our focus spans through all therapeutic areas, indications, and modalities, aiming to capture value and ultimately deliver breakthrough therapeutics to patients with high unmet needs. Our diverse and constantly updated project pipeline is a testament to our commitment. Contact us to explore what we have in the making.

Strategic Entrepreneurship / biotech
00:00
/
00:00
00:00
/
00:00
Strategic Entrepreneurship

To ensure the success of our ventures, we perform rigorous due diligence and develop R&D plans in collaboration with biopharma experts. We actively mature our early-stage ventures in-house and support them in fundraising by connecting them to our extensive investor network. Through our network of corporate exit partners, we ensure a successful journey towards exit, maximizing the impact of our innovations.

Established partnerships for scaled impact / biotech
00:00
/
00:00
00:00
/
00:00
Established partnerships for scaled impact

From improving diagnostic precision to developing new treatments, our biotech ventures are at the forefront of addressing significant unmet needs. By scaling these ventures together with our partners such as corporations and universities, our ultimate goal is to bring transformative scientific breakthroughs to patients, while creating value for our partners.

Biotech

portfolio

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Aerion Bioscience
Pioneering early lung cancer screening and saving lives

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

Active
🇱🇺 Luxembourg
Biotech
Aerion Bioscience
Karla Therapeutics
Innovating mental health treatments through neuroimmunology

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

Active
🇫🇷 France
Biotech
Karla Therapeutics
Lamina
The solution for effective cartilage regeneration

Lamina offers a solution for the regeneration of cartilage, addressing a prevalent issue affecting millions worldwide. Traditional treatments focus on symptom management or procedures like joint replacement, with limited success. Lamina's ARTiREG, enhances cell therapy with a special framework to hold Mesenchymal stem cells which repair for the body and help fix damaged cartilage. This patented approach promotes fast recovery, potentially transforming outcomes for individuals with cartilage damage.

Active
🇫🇷 France
Biotech
Lamina
Lumabs
Easy, fast, and sensitive point-of-care diagnostic platform

Lumabs introduces a revolutionary diagnostic platform offering quick and precise biomolecule measurement right at the point of care. By eliminating the need for time-consuming laboratory processes, such as ELISA tests, Lumabs ensures patients receive vital diagnostic results immediately. This innovation is crucial in emergency and intensive care settings, where real-time information can guide rapid treatment decisions, potentially saving lives.

Active
🇳🇱 Netherlands
Biotech
Lumabs
MLA Diagnostics
Personalised measurement of melanoma malignancy

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Active
🇳🇱 Netherlands
Biotech
MLA Diagnostics
NC Biomatrix
Regeneration of intervertebral disc as treatment for low back pain

NC Biomatrix offers a solution for treating low back pain caused by intervertebral disc (IVD) degeneration. Current treatments often come with complications and limited effectiveness. NC Biomatrix introduces an approach using a protein extract from pig nucleus pulposus, that stimulate disc regeneration. This extract provides a scaffold for natural tissue repair without damaging the surrounding. This injectable treatment aims to restore the degenerated disc, offering hope for effective relief from low back pain.

Active
🇳🇱 Netherlands
Biotech
Orthopedics & Spine
NC Biomatrix
NeurOdys Therapeutics
Developing treatments to slow or reverse Alzheimer's disease

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

Active
🇳🇱 Netherlands
Biotech
NeurOdys Therapeutics
Neurolieve BioSciences
Creating new treatments to relieve pain from diabetic nerve damage

Neurolieve BioSciences is developing innovative treatments for painful diabetic nerve damage, a common issue for people with diabetes. Current treatments, like antidepressants and opioids, often don't work well and can have serious side effects. Neurolieve BioSciences aims to provide effective pain relief by targeting a specific receptor that helps reduce nerve pain, offering a safer and more effective solution for those suffering from this condition.

Active
🇬🇧 United Kingdom
Biotech
Neurolieve BioSciences
Persuasive
Early and easy detection of ischemic heart disease

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

Active
🇳🇱 Netherlands
Biotech
Persuasive
ProVascTec
Transforming arterial disease treatment with cell therapy

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Active
🇮🇪 Ireland
Biotech
Cardiovascular
ProVascTec
Serda
Innovative enzymatic wound debrider offers fast, gentle healing solution

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

Active
🇳🇱 Netherlands
Biotech
Serda
Theragenix
Bone repair technology using gene therapy during surgery

TherageniX introduces an approach to improve bone implants by augmenting autologous bone grafts with regenerative gene therapies. Traditional bone repair methods face challenges like rejection, infection, and limited regenerative capacity. TherageniX's solution aims to enhance the regenerative bone grafts, improving functional outcomes and reducing donor trauma. This method bypasses regulatory and manufacturing hurdles, offering a promising advancement in bone grafting procedures.

Active
🇬🇧 United Kingdom
Biotech
Orthopedics & Spine
Theragenix
Xtrna Bio
Developing gene therapy to treat Charcot-Marie-Tooth disease

XtRNA Bio is developing a pioneering gene therapy to treat Charcot Marie Tooth (CMT) disease type 2D, leveraging tRNA supplementation therapies. Their patented treatment targets mutations in tRNA synthetases, offering a new therapeutic modality with vast potential for various diseases. They are raising €5M to develop a clinical candidate for CMT2D and expand their pipeline. CMT, a hereditary and heterogeneous disease, affects 1 in 2500 people worldwide, causing progressive muscle wasting, loss of sensation, and chronic pain, with no current cure.

Active
🇳🇱 Netherlands
Biotech
Xtrna Bio

Our impact

700+
Inventions assessed annually
10
Active portfolio ventures
€20M+
Raised by NLC ventures
200+
Industry partners
5
Countries active in
100M+
Patients targeted

Explore our 2023 impact report

background image behind a call to action
BioCurate
Smith and Nephew
NYU Langone Health
Radboud University
Hasselt University
University of Sheffield
University of Birmingham
CUIP
BioScience Valuation
Dr. Linda Pullan
I have had great conversations with the NLC team and I hope to listen and learn, as well as share my experiences to help shape NLC’s strategy as a supervisory board member.
Dr. Linda Pullan

Dr. Linda Pullan

Founder and Business Development Consultant at Pullan Consulting and NLC supervisory board member

Simon Loiodice
Since early 2022, I have been witnessing NLC’s growth and strategic positioning in the biopharma space. Highly international, the biotech team is skilled and deploys a pragmatic strategy. Working with this group is very rewarding!
Simon Loiodice

Simon Loiodice

Co-Founder and CEO of Karla Therapeutics and NLC advisor

Peter Suzdak
NLC has an impressive track record of bringing together innovators, management and capital to form new healthcare ventures. They have provided me with all the support I needed to successfully establish a biotech company.
Peter Suzdak

Peter Suzdak

Co-Founder and CEO of Midland Pharmaceuticals

get in touch to build a healthier future

Kathrin Ballesteros
Kathrin Ballesteros
Portfolio Management
Lydia Kalafateli
Lydia Kalafateli
Venture Creation